Citadel Advisors
OMGA

Citadel Advisors’s Omega Therapeutics, Inc. Common Stock OMGA Stock Holding History

Citadel Advisors’s Portfolio OMGA Stock Details OMGA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-24,600
Closed -$18.3K – 15960
2024
Q4 		$18.3K Buy
24,600
+18,700
+317% +$18.6K ﹤0.01% 13235
2024
Q3 		$7.2K Sell
5,900
-11,400
-66% -$18.2K ﹤0.01% 13375
2024
Q2 		$35.8K Buy
17,300
+6,300
+57% +$14.9K ﹤0.01% 12097
2024
Q1 		$40.1K Buy
+11,000
New +$42.2K ﹤0.01% 12387
2023
Q4 		– Sell
-18,600
Closed -$40K – 15450
2023
Q3 		$40K Buy
18,600
+15,400
+481% +$61.6K ﹤0.01% 11994
2023
Q2 		$17.9K Sell
3,200
-4,600
-59% -$36K ﹤0.01% 12831
2023
Q1 		$47K Sell
7,800
-1,300
-14% -$9.05K ﹤0.01% 12238
2022
Q4 		$52K Sell
9,100
-3,300
-27% -$18.5K ﹤0.01% 12085
2022
Q3 		$67K Buy
+12,400
New +$62.8K ﹤0.01% 11418

Other funds holding OMGA

Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
PS
Principal Securities Des Moines, Iowa $6.82B AUM 17.15% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Citadel Advisors's OMGA Position: Q1 2025 in Review

Citadel Advisors sold out of Omega Therapeutics, Inc. Common Stock (OMGA) in Q1 2025, closing a stake of 49 shares — an estimated $37 sold.

Citadel Advisors first reported a position in OMGA in Q2 2022 and held it in 10 quarters. The position peaked at $2.14M in Q2 2024. 4 funds tracked by Wall St. Rank hold OMGA as of Q1 2025.

  • Citadel Advisors reported no remaining Omega Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Citadel Advisors sold 49 Omega Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $37.
  • Citadel Advisors first reported a position in Omega Therapeutics, Inc. Common Stock in Q2 2022 and held it in 10 quarters.
  • Citadel Advisors's Omega Therapeutics, Inc. Common Stock position peaked at $2.14M in Q2 2024.
  • 4 funds tracked by Wall St. Rank held Omega Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.